99% OF PATIENTS GOT TO T GOAL BY DAY 7

Drop in T Levels

Patient Castrate Levels

Reduction in PSA Levels

FIRMAGON^®
(degarelix for injection) HELPED 52% OF PATIENTS REACH CASTRATE LEVELS (T ≤50 ng/dL)
ON DAY 1^1,2

View Safety Profile

PERCENTAGE OF
PATIENTS
ACHIEVING
CASTRATE LEVELS¹*

Half of Firmagon® patients reached castrate level goals on day 1

Study Design

The pivotal phase 3 trial (CS21) was a 3-armed, randomized (1:1:1), active-controlled, open-label, parallel-group, 12-month clinical study of FIRMAGON compared to leuprolide acetate (Lupron Depot^®).³ Serum levels of testosterone were measured at screening, on days 0, 1, 3, 7, 14,
and 28 in the first month, and then monthly until the end of the study.¹

PRIMARY ENDPOINT³:

FIRMAGON was shown to maintain testosterone suppression below castration level (≤50 ng/dL) during 12 months of treatment.

KEY SECONDARY ENDPOINTS³:

Proportion of patients with testosterone ≤50 ng/dL
Serum levels of testosterone, prostate-specific antigen (PSA), luteinizing hormone (LH), and follicle-stimulating hormone (FSH) over time
Percentage change in PSA from baseline to 14-28 days

Abbreviations: T = testosterone.

Monthly Matters

Help make the most of your patient's
treatment experience

Make the most of monthly visits. Help your patients feel connected to their therapy through the reassurance of regular treatment and progress check-ins. Ferring is here to help enhance this connection at every step.

One-month depot is ideal for my patients. They love to come in, get checked, and see their nurse practitioner to ask questions and get updated data about their condition.

Actual physician quote

REFERENCES: 1. FIRMAGON^® [package insert]. Parsippany, NJ: Ferring Pharmaceuticals Inc. 2. Data on file. Ferring Pharmaceuticals Inc. 3. Klotz L, Boccon-Gibod L, Shore ND, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008;102(11):1531-1538.

Indication

FIRMAGON^® (degarelix for injection) is a GnRH receptor antagonist indicated for treatment of patients with advanced prostate cancer.

Important Safety Information

FIRMAGON is contraindicated in patients with a history of severe hypersensitivity to degarelix or to any of the product components.

Hypersensitivity reactions, including anaphylaxis, urticaria, and angioedema, have been reported post-marketing with FIRMAGON. In case of a serious hypersensitivity reaction, discontinue FIRMAGON immediately if the injection has not been completed, and manage as clinically indicated. Patients with a known history of severe hypersensitivity reactions to FIRMAGON should not be re-challenged with FIRMAGON.

FIRMAGON is contraindicated in women who are or may become pregnant. FIRMAGON can cause fetal harm and loss of pregnancy when administered to a pregnant woman.

Long-term androgen deprivation therapy (ADT) may prolong the QT interval. Physicians should consider whether the benefits of ADT outweigh the potential risks in patients with congenital long QT syndrome, electrolyte abnormalities, or congestive heart failure and in patients taking drugs known to prolong the QT interval (e.g., Class IA or Class III antiarrhythmic medications.)

Therapy with FIRMAGON results in suppression of the pituitary gonadal system. Results of diagnostic tests of the pituitary gonadotropic and gonadal functions conducted during and after FIRMAGON may be affected. The therapeutic effect of FIRMAGON should be monitored by measuring serum concentrations of prostate-specific antigen (PSA) periodically. If PSA increases, serum concentrations of testosterone should be measured.

The most common adverse reactions (≥10%) during FIRMAGON therapy included injection site reactions (e.g., pain, erythema, swelling, induration or inflammation), pyrexia, hot flashes, weight loss or gain, fatigue, and increases in serum levels of transaminases and gamma-glutamyltransferase. The majority of adverse reactions were Grade 1 or 2; 1% or less were Grade 3/4. Injection site reactions were mostly transient, of mild to moderate intensity, occurred primarily with the starting dose, and led to few discontinuations (<1%).

You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.FDA.gov/medwatch or call 1-800-FDA-1088.

You may also contact Ferring Pharmaceuticals Inc. at 1-888-FERRING.

99% OF PATIENTS GOT TO T GOAL BY DAY 7

FIRMAGON® (degarelix for injection) HELPED 52% OF PATIENTS REACH CASTRATE LEVELS (T ≤50 ng/dL) ON DAY 11,2

PERCENTAGE OF PATIENTS ACHIEVING CASTRATE LEVELS1*

Study Design

PRIMARY ENDPOINT3:

KEY SECONDARY ENDPOINTS3: